Historical perspective and future directions in platelet research

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 1 S, 2011, Pages 374-395

  Coller, B S ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Aspirin; History; Platelets; Thrombocytopenia; Thrombosis; Willebrand

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADRENALIN; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; COLLAGEN; CORTICOSTEROID; CYTOCHROME P450 2C19; FIBRINOGEN; G PROTEIN COUPLED RECEPTOR; HEPATITIS B VACCINE; LEUCINE RICH REPEAT KINASE 2; LIGAND; METHIONINE; PADGEM PROTEIN; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; SEROTONIN; TETRASPANIN; THROMBIN; THROMBOCYTE RECEPTOR; THROMBOCYTE SLOWING FACTOR; THROMBOPOIETIN; THROMBOSPONDIN 1; TICLOPIDINE; UNINDEXED DRUG; VASOPRESSIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE CORONARY SYNDROME; AFIBRINOGENEMIA; ANGIOGENESIS; ANTIBACTERIAL ACTIVITY; ARTERY THROMBOSIS; AUTOIMMUNE THROMBOCYTOPENIA; BERNARD SOULIER DISEASE; BIOCHEMISTRY; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; BONE MARROW TOXICITY; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL INTERACTION; CHORION VILLUS SAMPLING; CORONARY STENT; CORTICOSTEROID THERAPY; CRYOPRESERVATION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; EXOCYTOSIS; GAS EXCHANGE; GENETIC VARIABILITY; GLANZMANN DISEASE; HEMATOLOGIC DISEASE; HEMOPHILIA; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HETEROZYGOTE DETECTION; HISTORICAL PERIOD; HLA MATCHING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFLAMMATION; ISOTOPE LABELING; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MEGAKARYOCYTE; MEGAKARYOPOIESIS; METASTASIS; MOLECULAR DIAGNOSIS; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NEUTROPENIA; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PH; PLATELET LEUKOCYTE INTERACTION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SEROLOGY; SPLENECTOMY; STEM CELL TRANSPLANTATION; STROKE; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPOIESIS; THROMBOSIS; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSGENIC MOUSE; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; TUMOR GROWTH; ULTRAVIOLET IRRADIATION; UNSTABLE ANGINA PECTORIS; UREMIA; VACCINATION; VON WILLEBRAND DISEASE; WOUND HEALING;

BIOMEDICAL RESEARCH; BLOOD PLATELETS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; THROMBOSIS;

EID: 79960634960     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04356.x     Document Type: Review

References (418)

1. Lopez A, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global Burden of Disease and Risk Factors. Oxford: Oxford University Press and the World Bank, 2006.
2. Bizzozero G. Su di un nuovo elemento morfologico del sangue dei mammiferi e della sua importanza nella trombosi e nella coagulazione. L'Osservatore 1881; 17: 785-7.
3. Bizzozero J. Uber einen neuen formbestandteil des blutes und dessen rolle bei der thrombose und blutgerinnung. Virchows Arch 1882; 90: 261-332.
4. Robb-Smith AH. Why the platelets were discovered. Br J Haematol 1967; 13: 618-37.
5. Tocantins LM. Historical notes on blood platelets. Blood 1948; 3: 1073-82.
6. Bizzozero G. Sul midollo delle ossa. Il Morgagni. 1869.
7. Wright JH. The origin and nature of blood plates. Boston Med Surg J 1906; 154: 643-5.
8. Lee RE, Young RH, Castleman B. James Homer Wright: a biography of the enigmatic creator of the Wright stain on the occasion of its centennial. Am J Surg Pathol 2002; 26: 88-96.
9. Osler W. On certain problems in the physiology of the blood corpuscles. Med News 1886; 48: 421-5.
10. Marcus AJ, Zucker MB. The Physiology of Blood Platelets. New York, NY: Gurne and Stratton, Inc., 1965.
11. Spaet TH. Platelets: the blood dust. In: Wintrobe M, ed. Blood, Pure and Eloquent. New York, NY: McGraw-Hill, Inc, 1980: 549-71.
12. de Gaetano G. Historical overview of the role of platelets in hemostasis and thrombosis. Haematologica 2001; 86: 349-56.
13. Michelson AD, ed. Platelets. Burlington, MA: Academic Press, 2007.
14. Jones HW, Tocantins LM. The history of purpura hemorrhagica. Ann Med Hist 1933; 5: 349-64.
15. Saito H, Kunishima S. Historical hematology: May-Hegglin anomaly. Am J Hematol 2008; 83: 304-6.
16. Duke WW. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and the coagulation time and report of three cases of hemorrhagic disease relieved by transfusion. JAMA 1910; 55: 1185-92.
17. Glanzmann E. Hereditäre hämmorhagische Thrombasthenie. Ein Beitrag zur Pathologie der Blutplättchen. Jahrbuch fur Kinderheilkunde und physiche Erziehung 1918; 88: 113-41.
18. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924; 24: 21-4.
19. Moake JL. Thrombotic thrombocytopenic purpura: survival by "giving a dam". Trans Am Clin Climatol Assoc 2004; 115: 201-19.
20. von Willebrand EA. Hereditar pseudoemophili. Fin Lakaresallsk Handl 1926; 68: 87-112.
21. Federici AB, Berntorp E, Lee CA. The 80th anniversary of von Willebrand's disease: history, management and research. Haemophilia 2006; 12: 563-72.
22. Koutts J. A short history of diagnostic tests for von Willebrand disease: in memory of Barry Firkin (1930 to 2001) and Ted Zimmerman (1937 to 1988). Semin Thromb Hemost 2006; 32: 445-55.
23. Bernard J. History of congenital hemorrhagic thrombocytopathic dystrophy. Blood Cells 1983; 9: 179.
24. Budtz-Olsen OE. Clot Retraction. Springfield: Charles Thomas, 1951.
25. Hovig T. The early discoveries of collagen-platelet interaction and studies on its role in hemostatic plug formation. J Thromb Haemost 2005; 3: 1-6.
26. Zucker MB, Friedman BK, Rapport MM. Identification and quantitative determination of serotonin (5-hydroxytryptamine) in blood platelets. Proc Soc Exp Biol Med 1954; 85: 282-5.
27. Bounameaux H. More on: the early discoveries of collagen-platelet interaction and studies on its role in hemostatic plug formation. J Thromb Haemost 2005; 3: 1116.
28. Bettex-Galland M, Portzehl H, Luscher EF. Dissociation of thrombosthenin into two components comparable with actin and myosin. Nature 1962; 193: 777-8.
29. Bettex-Galland M, Clemetson KJ. First isolation of actomyosin from a non-muscle cell: first isolated platelet protein. J Thromb Haemost 2005; 3: 834-9.
30. Harrington J, Minnich V, Hollingsworth JW. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951; 38: 1-10.
31. Harrington WJ, Sprague CC, Minnich V. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953; 38: 433.
32. Nilsson IM, Blomback M, Blomback B. v. Willebrand's disease in Sweden; its pathogenesis and treatment. Acta Med Scand 1959; 164: 263-78.
33. Nilsson IM, Blomback M, Jorpes E, Blomback B, Johansson SA. von Willebrand's disease and its correction with human plasma fraction 1-0. Acta Med Scand 1957; 159: 179-88.
34. Goldstein AB. Dual hemostatic defect in pseudohemophilia. J Clin Invest 1953; 32: 1551.
35. Larrieu MJ, Soulier JP. Deficiency of antihemophilic factor A in a girl associated with bleeding disorder. Rev Hematol 1953; 8: 361-70.
36. Jurgens R, Lehmann W, Wegelius O, Eriksson AW, Hiepler E. Antihemophilic globulin (factor VIII) deficiency in Aland (Willebrand-Jurgens) thrombopathy. Thromb Diath Haemorrh 1957; 1: 257-60.
37. Cronkite EP, Jacobs GJ, Brecher G, Dillard G. The hemorrhagic phase of the acute radiation syndrome due to exposure of the whole body to penetrating ionizing radiation. Am J Roentgenol Radium Ther Nuc Med 1952; 67: 796-803.
38. Cronkite EP, Jackson DP. The use of platelet transfusions in hemorrhagic disease. In: Toscantine LM, ed. Progress in Hematology Vol. 2. New York, NY: Grune and Stratton, 1959: 239.
39. Gardner FH, Cohen P. The value of platelet transfusions. Med Clin North Am 1960; 44: 1425-39.
40. Kaznelson P. Verschwinden den haemorrhagischen Diathese bei einem Fallen von essentieller Thrombopenie (Frank) nach Milz Extirpation. Splenogene thrombolitische Purpura. Wien Klin Wochenschr 1916; 29: 1451-4.
41. Dameshek W, Rubio F Jr, Mahoney JP, Reeves WH, Burgin LA. Treatment of idiopathic thrombocytopenic purpura (ITP) with prednisone. J Am Med Assoc 1958; 166: 1805-15.
42. Kelemen E, Cserhati I, Tanos B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol 1958; 20: 350-5.
43. McDonald TP, Andrews RB, Clift R, Cottrell M. Characterization of a thrombocytopoietic-stimulating factor from kidney cell culture medium. Exp Hematol 1981; 9: 288-96.
44. Hill RJ, Leven RM, Levin FC, Levin J. The effect of partially purified thrombopoietin on guinea pig megakaryocyte ploidy in vitro. Exp Hematol 1989; 17: 903-7.
45. Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 2008; 111: 981-6.
46. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ, Oles KJ, Hultgren B, Solberg LA, Goeddel DV, Eaton DL. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533-8.
47. Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F, Chang MS, Samal B, Nichol JL, Swift S, Johnson MJ, Hsu RY, Parker VP, Suggs S, Skrine JD, Merewether LA, Clogston C, Hsu E, Hokom MM, Hornkohl A, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77: 1117-24.
48. Sohma Y, Akahori H, Seki N, Hori T, Ogami K, Kato T, Shimada Y, Kawamura K, Miyazaki H. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1994; 353: 57-61.
49. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 1994; 91: 11104-8.
50. Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, Krukemeier S, Eilers M, Strauss G, Welte K. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001; 97: 139-46.
51. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85: 2720-30.
52. Jackson CW. Megakaryocyte endomitosis: a review. Int J Cell Cloning 1990; 8: 224-6, doi: .
53. Kostyak JC, Naik UP. Calcium- and integrin-binding protein 1 regulates endomitosis and its interaction with Polo-like kinase 3 is enhanced in endomitotic Dami cells. PLoS ONE 2011; 6: e14513.
54. McCrann DJ, Eliades A, Makitalo M, Matsuno K, Ravid K. Differential expression of NADPH oxidases in megakaryocytes and their role in polyploidy. Blood 2009; 114: 1243-9.
55. Lordier L, Jalil A, Aurade F, Larbret F, Larghero J, Debili N, Vainchenker W, Chang Y. Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. Blood 2008; 112: 3164-74.
56. Richardson JL, Shivdasani RA, Boers C, Hartwig JH, Italiano JE Jr. Mechanisms of organelle transport and capture along proplatelets during platelet production. Blood 2005; 106: 4066-75.
57. Patel SR, Richardson JL, Schulze H, Kahle E, Galjart N, Drabek K, Shivdasani RA, Hartwig JH, Italiano JE Jr. Differential roles of microtubule assembly and sliding in proplatelet formation by megakaryocytes. Blood 2005; 106: 4076-85.
58. Patel SR, Hartwig JH, Italiano JE Jr. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest 2005; 115: 3348-54.
59. Stenberg PE, Levin J. Mechanisms of platelet production. Blood Cells 1989; 15: 23-47.
60. Italiano JE Jr, Lecine P, Shivdasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol 1999; 147: 1299-312.
61. Junt T, Schulze H, Chen Z, Massberg S, Goerge T, Krueger A, Wagner DD, Graf T, Italiano JE Jr, Shivdasani RA, von Andrian UH. Dynamic visualization of thrombopoiesis within bone marrow. Science 2007; 317: 1767-70.
62. Klusmann JH, Godinho FJ, Heitmann K, Maroz A, Koch ML, Reinhardt D, Orkin SH, Li Z. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev 2010; 24: 1659-72.
63. Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 2009; 113: 2619-28.
64. Majerus PW, Baenziger NL, Brodie GN. Lipid metabolism in human platelets. Ser Haematol 1971; 4: 59-74.
65. Hellem AJ, Borchgrevink CF, Ames SB. The role of red cells in haemostasis: the relation between haematocrit, bleeding time and platelet adhesiveness. Br J Haematol 1961; 7: 42-50.
66. Gaarder A, Jonsen J, Laland S, Hellem AJ, Owren P. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-2.
67. Salzman EW, Neri LL. Adhesiveness of blood platelets in uremia. Thromb Diath Haemorrh. 1966; 15: 84-92.
68. Bowie EJ, Owen CA Jr, Thompson JH, Didisheim P. Platelet adhesiveness in von Willebrand's disease. Am J Clin Pathol 1969; 52: 69-77.
69. Zucker MB, Brownlea S, McPherson J. Insights into the mechanism of platelet retention in glass bead columns. Ann N Y Acad Sci 1987; 516: 398-406.
70. Bouma BN, Wiegerinck Y, Sixma JJ, van Mourik JA, Mochtar IA. Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in von Willebrand's disease. Nat New Biol 1972; 236: 104-6.
71. White JG, Clawson CC. Overview article: biostructure of blood platelets. Ultrastruct Pathol 1980; 1: 533-58.
72. Niewiarowski S. Proteins secreted by the platelet. Thromb Haemost 1977; 38: 924-38.
73. Baenziger NL, Brodie GN, Majerus PW. Isolation and properties of a thrombin-sensitive protein of human platelets. J Biol Chem 1972; 247: 2723-31.
74. Holmsen H, Weiss HJ. Hereditary defect in the platelet release reaction caused by a deficiency in the storage pool of platelet adenine nucleotides. Br J Haematol 1970; 19: 643-9.
75. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-9.
76. O'Brien J. Platelet aggregation. II. Some results from a new method of study. J Clin Pathol 1962; 15: 452-81.
77. Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 1976; 261: 558-60.
78. Day HJ, Holmsen H. Concepts of the blood platelet release reaction. Ser Haematol 1971; 4: 3-27.
79. Haslam RJ, Davidson MM, Fox JE, Lynham JA. Cyclic nucleotides in platelet function. Thromb Haemost 1978; 40: 232-40.
80. Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets 2001; 12: 261-73.
81. Charo IF, Feinman RD, Detwiler TC. Interrelations of platelet aggregation and secretion. J Clin Invest 1977; 60: 866-73.
82. Kawahara Y, Takai Y, Minakuchi R, Sano K, Nishizuka Y. Possible involvement of Ca2+-activated, phospholipid-dependent protein kinase in platelet activation. J Biochem 1980; 88: 913-6.
83. Takai Y, Kaibuchi K, Sano K, Nishizuka Y. Counteraction of calcium-activated, phospholipid-dependent protein kinase activation by adenosine 3', 5'-monophosphate and guanosine 3', 5'-monophosphate in platelets. J Biochem 1982; 91: 403-6.
84. Siess W, Siegel FL, Lapetina EG. Arachidonic acid stimulates the formation of 1, 2-diacylglycerol and phosphatidic acid in human platelets. Degree of phospholipase C activation correlates with protein phosphorylation, platelet shape change, serotonin release, and aggregation. J Biol Chem 1983; 258: 11236-42.
85. Majerus PW, Wilson DB, Connolly TM, Bross TE, Neufeld EJ. Pathways of phosphoinositide metabolism in human platelets. Adv Prostaglandin Thromboxane Leukot Res 1985; 15: 109-12.
86. Billah MM, Lapetina EG, Cuatrecasas P. Phospholipase A2 and phospholipase C activities of platelets. Differential substrate specificity, Ca2+ requirement, pH dependence, and cellular localization. J Biol Chem 1980; 255: 10227-31.
87. Zucker MB, Pert JH, Hilgartner MW. Platelet function in a patient with thrombasthenia. Blood 1966; 28: 524.
88. Weiss HJ, Kochwa S. Studies of platelet function and proteins in 3 patients with Glanzmann's thrombasthenia. J Lab Clin Med 1968; 71: 153-65.
89. Caen JP, Castaldi PA, Leclerc JC, Inceman S, Larrieu MJ, Probst M, Bernard J. Congenital bleeding disorders with long bleeding time and normal platelet count. I. Glanzmann's thrombasthenia. Am J Med 1966; 41: 4.
90. Jenkins CS, Phillips DR, Clemetson KJ, Meyer D, Larrieu MJ, Luscher EF. Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease. J Clin Invest 1976; 57: 112-24.
91. Holmsen H, Weiss HJ. Further evidence for a deficient storage pool of adenine nucleotides in platelets from some patients with thrombocytopathia -"storage pool disease". Blood 1972; 39: 197-209.
92. Raccuglia G. Gray platelet syndrome. A variety of qualitative platelet disorder. Am J Med 1971; 51: 818-28.
93. Lages B, Malmsten C, Weiss HJ, Samuelsson B. Impaired platelet response to thromboxane-A2 and defective calcium mobilization in a patient with a bleeding disorder. Blood 1981; 57: 545-52.
94. Day HJ, Rao AK. Evaluation of platelet function. Semin Hematol 1986; 23: 89-101.
95. Peerschke EI. The platelet fibrinogen receptor. Semin Hematol 1985; 22: 241-59.
96. Bennett JS. The platelet-fibrinogen interaction. In: George JN, Nurden AT, Phillips DR, eds. Platelet Membrane Glycoproteins. New York, NY: Plenum, 1985: 193.
97. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-43.
98. Plow EF, Ginsberg MH. Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 1989; 9: 117-56.
99. Solum NO, Clemetson KJ. The discovery and characterization of platelet GPIb. J Thromb Haemost 2005; 3: 1125-32.
100. Sakariassen KS, Turitto VT, Baumgartner HR. Recollections of the development of flow devices for studying mechanisms of hemostasis and thrombosis in flowing whole blood. J Thromb Haemost 2004; 2: 1681-90.
101. de Groot PG, MJ IJ, Sixma JJ. Platelet adhesion to the subendothelium under flow. Methods Mol Biol 1999; 96: 159-70.
102. Ruggeri ZM. Platelet adhesion under flow. Microcirculation 2009; 16: 58-83.
103. Weiss HJ. Flow-related platelet deposition on subendothelium. Thromb Haemost 1995; 74: 117-22.
104. Alkjaersig N, Abe T, Seegers WH. Purification and quantitative determination of platelet factor 3. Am J Physiol 1955; 181: 304-8.
105. Solum NO. Procoagulant expression in platelets and defects leading to clinical disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2841-6.
106. Marcus AJ, Spaet TH. Platelet phosphatides: their separation, identification, and clotting activity. J Clin Invest 1958; 37: 1836-47.
107. Nesheim ME, Furmaniak-Kazmierczak E, Henin C, Cote G. On the existence of platelet receptors for factor V(a) and factor VIII(a). Thromb Haemost 1993; 70: 80-6.
108. Majerus PW, Miletich JP. Relationships between platelets and coagulation factors in hemostasis. Annu Rev Med 1978; 29: 41-9.
109. Walsh PN. Platelet coagulation-protein interactions. Semin Thromb Hemost 2004; 30: 461-71.
110. Beguin S, Kumar R, Keularts I, Seligsohn U, Coller BS, Hemker HC. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 1999; 93: 564-70.
111. Morel O, Morel N, Freyssinet JM, Toti F. Platelet microparticles and vascular cells interactions: a checkpoint between the haemostatic and thrombotic responses. Platelets 2008; 19: 9-23.
112. Flaumenhaft R, Mairuhu AT, Italiano JE. Platelet- and megakaryocyte-derived microparticles. Semin Thromb Hemost 2010; 36: 881-7.
113. Weiss HJ, Vicic WJ, Lages BA, Rogers J. Isolated deficiency of platelet procoagulant activity. Am J Med 1979; 67: 206-13.
114. Zwaal RF, Comfurius P, Bevers EM. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta 2004; 1636: 119-28.
115. Weiss HJ. Scott syndrome - a disorder of platelet coagulant activity. Semin Hematol 1994; 31: 312-9.
116. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation on the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 137-48.
117. Boettcher JM, Davis-Harrison RL, Clay MC, Nieuwkoop AJ, Ohkubo YZ, Tajkhorshid E, Morrissey JH, Rienstra CM. Atomic view of calcium-induced clustering of phosphatidylserine in mixed lipid bilayers. Biochemistry 2011; 50: 2264-73.
118. Koklic T, Majumder R, Weinreb GE, Lentz BR. Factor XA binding to phosphatidylserine-containing membranes produces an inactive membrane-bound dimer. Biophys J 2009; 97: 2232-41.
119. Ohkubo YZ, Tajkhorshid E. Distinct structural and adhesive roles of Ca2+ in membrane binding of blood coagulation factors. Structure 2008; 16: 72-81.
120. Weiss HJ. Impaired platelet procoagulant mechanisms in patients with bleeding disorders. Semin Thromb Hemost 2009; 35: 233-41.
121. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-5.
122. Weksler BB, Marcus AJ, Jaffe EA. Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci USA 1977; 74: 3922-6.
123. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-46.
124. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057-8.
125. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001; 88: 756-62.
126. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley KA, Gayle RB, Maliszewski CR. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997; 99: 1351-60.
127. Marcus AJ, Broekman MJ, Drosopoulos JH, Olson KE, Islam N, Pinsky DJ, Levi R. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost 2005; 31: 234-46.
128. Johnston-Cox HA, Yang D, Ravid K. Physiological implications of adenosine receptor-mediated platelet aggregation. J Cell Physiol 2011; 226: 46-51.
129. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008; 1783: 673-94.
130. Koszalka P, Ozuyaman B, Huo Y, Zernecke A, Flogel U, Braun N, Buchheiser A, Decking UK, Smith ML, Sevigny J, Gear A, Weber AA, Molojavyi A, Ding Z, Weber C, Ley K, Zimmermann H, Godecke A, Schrader J. Targeted disruption of cd73/ecto-5'-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res 2004; 95: 814-21.
131. Marcus AJ. The role of lipids in platelet function: with particular reference to the arachidonic acid pathway. J Lipid Res 1978; 19: 793-826.
132. Marcus AJ, Safier LB, Broekman MJ, Islam N, Fliessbach JH, Hajjar KA, Kaminski WE, Jendraschak E, Silverstein RL, von Schacky C. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Thromb Haemost 1995; 74: 213-7.
133. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008; 111: 5271-81.
134. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010; 30: 2357-61.
135. Semple JW, Freedman J. Platelets and innate immunity. Cell Mol Life Sci 2010; 67: 499-511.
136. Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, French PA, Dauerman HL, Becker RC. Platelet functions beyond hemostasis. J Thromb Haemost 2009; 7: 1759-66.
137. Bergmeier W, Chauhan AK, Wagner DD. Glycoprotein Ibalpha and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemost 2008; 99: 264-70.
138. Andrews RK, Lopez JA, Berndt MC. Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol 1997; 29: 91-105.
139. Ruggeri ZM. Von Willebrand factor: looking back and looking forward. Thromb Haemost 2007; 98: 55-62.
140. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102: 449-61.
141. Clemetson KJ, Clemetson JM. Collagen receptors as potential targets for novel anti-platelet agents. Curr Pharm Des 2007; 13: 2673-83.
142. Rink TJ. Cytosolic calcium in platelet activation. Experientia 1988; 44: 97-100.
143. Oda A, Daley JF, Kang J, Smith M, Ware JA, Salzman EW. Quasi-simultaneous measurement of ionized calcium and alpha-granule release in individual platelets. Am J Physiol 1991; 260: C242-8.
144. Nurden AT, Phillips DR, George JN. Platelet membrane glycoproteins: historical perspectives. J Thromb Haemost 2006; 4: 3-9.
145. George JN, Nurden AT, Phillips DR. Molecular defects in interactions of platelets with the vessel wall. N Engl J Med 1984; 311: 1084.
146. Nurden AT, Didry D, Kieffer N, McEver RP. Residual amounts of glycoproteins IIb and IIIa may be present in the platelets of most patients with Glanzmann's thrombasthenia. Blood 1985; 65: 1021-4.
147. George JN, Narden AT, Phillips DR, eds. Platelet Membrane Glycoproteins. New York, NY: Plenum, 1985.
148. McEver RP, Baenziger NL, Majerus PW. Isolation and quantitation of the platelet membrane glycoprotein deficient in thrombasthenia using a monoclonal hybridoma antibody. J Clin Invest 1980; 66: 1311-8.
149. Bennett JS, Hoxie JA, Leitman SF, Vilaire G, Cines DB. Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. Proc Natl Acad Sci USA 1983; 80: 2417-21.
150. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
151. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 1983; 61: 99-110.
152. Coller BS, Beer JH, Scudder LE, Steinberg MH. Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIa mediated by adhesive proteins. Blood 1989; 74: 182-92.
153. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-14.
154. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 880-6.
155. Berman CL, Yeo EL, Wencel-Drake JD, Furie BC, Ginsberg MH, Furie B. A platelet alpha granule membrane protein that is associated with the plasma membrane after activation. Characterization and subcellular localization of platelet activation-dependent granule-external membrane protein. J Clin Invest 1986; 78: 130-7.
156. Frelinger AL III, Cohen I, Plow EF, Smith MA, Roberts J, Lam SC, Ginsberg MH. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem 1990; 265: 6346-52.
157. Adelman B, Michelson AD, Handin RI, Ault KA. Evaluation of platelet glycoprotein Ib by fluorescence flow cytometry. Blood 1985; 66: 423-7.
158. Johnston GI, Pickett EB, McEver RP, George JN. Heterogeneity of platelet secretion in response to thrombin demonstrated by fluorescence flow cytometry. Blood 1987; 69: 1401-3.
159. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-15.
160. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-38.
161. George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, Newman PJ. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78: 340-8.
162. Goschnick MW, Jackson DE. Tetraspanins-structural and signalling scaffolds that regulate platelet function. Mini Rev Med Chem 2007; 7: 1248-54.
163. Orlowski E, Chand R, Yip J, Wong C, Goschnick MW, Wright MD, Ashman LK, Jackson DE. A platelet tetraspanin superfamily member, CD151, is required for regulation of thrombus growth and stability in vivo. J Thromb Haemost 2009; 7: 2074-84.
164. Brass LF, Manning DR, Cichowski K, Abrams CS. Signaling through G proteins in platelets: to the integrins and beyond. Thromb Haemost 1997; 78: 581-9.
165. Shankar H, Kahner B, Kunapuli SP. G-protein dependent platelet signaling - perspectives for therapy. Curr Drug Targets 2006; 7: 1253-63.
166. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309: 30-3.
167. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie G, Ginsberg MH. Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets. Blood 1987; 70: 110-5.
168. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004; 432: 59-67.
169. Ruggeri ZM, Zarpellon A, Roberts JR, McClintock RA, Jing H, Mendolicchio GL. Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib. Thromb Haemost 2010; 104: 894-902.
170. Dumas JJ, Kumar R, McDonagh T, Sullivan F, Stahl ML, Somers WS, Mosyak L. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J Biol Chem 2004; 279: 23327-34.
171. Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, de Groot PG, Sixma JJ, Gros P. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 2002; 297: 1176-9.
172. Zhu J, Luo BH, Barth P, Schonbrun J, Baker D, Springer TA. The structure of a receptor with two associating transmembrane domains on the cell surface: integrin alphaIIbbeta3. Mol Cell 2009; 34: 234-49.
173. Ye F, Hu G, Taylor D, Ratnikov B, Bobkov AA, McLean MA, Sligar SG, Taylor KA, Ginsberg MH. Recreation of the terminal events in physiological integrin activation. J Cell Biol 2010; 188: 157-73.
174. Jirouskova M, Shet AS, Johnson GJ. A guide to murine platelet structure, function, assays, and genetic alterations. J Thromb Haemost 2007; 5: 661-9.
175. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood 2007; 109: 1503-6.
176. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-14.
177. Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989; 84: 1440-5.
178. Clemetson JM, Polgar J, Magnenat E, Wells TN, Clemetson KJ. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J Biol Chem 1999; 274: 29019-24.
179. Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. Thromb Res 2004; 114: 221-33.
180. Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost 2005; 3: 1752-62.
181. Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-40.
182. Ozaki Y, Asazuma N, Suzuki-Inoue K, Berndt MC. Platelet GPIb-IX-V-dependent signaling. J Thromb Haemost 2005; 3: 1745-51.
183. Asazuma N, Ozaki Y, Satoh K, Yatomi Y, Handa M, Fujimura Y, Miura S, Kume S. Glycoprotein Ib-von Willebrand factor interactions activate tyrosine kinases in human platelets. Blood 1997; 90: 4789-98.
184. Mazzucato M, Pradella P, Cozzi MR, De Marco L, Ruggeri ZM. Sequential cytoplasmic calcium signals in a 2-stage platelet activation process induced by the glycoprotein Ibalpha mechanoreceptor. Blood 2002; 100: 2793-800.
185. Berndt MC, Shen Y, Dopheide SM, Gardiner EE, Andrews RK. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001; 86: 178-88.
186. Shattil SJ. The beta3 integrin cytoplasmic tail: protein scaffold and control freak. J Thromb Haemost 2009; 7 (Suppl. 1): 210-3.
187. Zou Z, Chen H, Schmaier AA, Hynes RO, Kahn ML. Structure-function analysis reveals discrete beta3 integrin inside-out and outside-in signaling pathways in platelets. Blood 2007; 109: 3284-90.
188. Angelillo-Scherrer A, Burnier L, Flores N, Savi P, DeMol M, Schaeffer P, Herbert JM, Lemke G, Goff SP, Matsushima GK, Earp HS, Vesin C, Hoylaerts MF, Plaisance S, Collen D, Conway EM, Wehrle-Haller B, Carmeliet P. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest 2005; 115: 237-46.
189. Gong H, Shen B, Flevaris P, Chow C, Lam SC, Voyno-Yasenetskaya TA, Kozasa T, Du X. G protein subunit Galpha13 binds to integrin alphaIIbbeta3 and mediates integrin "outside-in" signaling. Science 2010; 327: 340-3.
190. Senis YA, Antrobus R, Severin S, Parguina AF, Rosa I, Zitzmann N, Watson SP, Garcia A. Proteomic analysis of integrin alphaIIbbeta3 outside-in signaling reveals Src-kinase-independent phosphorylation of Dok-1 and Dok-3 leading to SHIP-1 interactions. J Thromb Haemost 2009; 7: 1718-26.
191. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2008; 112: 3011-25.
192. Lau TL, Kim C, Ginsberg MH, Ulmer TS. The structure of the integrin alphaIIbbeta3 transmembrane complex explains integrin transmembrane signalling. EMBO J 2009; 28: 1351-61.
193. Metcalf DG, Moore DT, Wu Y, Kielec JM, Molnar K, Valentine KG, Wand AJ, Bennett JS, DeGrado WF. NMR analysis of the alphaIIb beta3 cytoplasmic interaction suggests a mechanism for integrin regulation. Proc Natl Acad Sci U S A 2010; 107: 22481-6. 1.
194. Yang J, Ma YQ, Page RC, Misra S, Plow EF, Qin J. Structure of an integrin alphaIIb beta3 transmembrane-cytoplasmic heterocomplex provides insight into integrin activation. Proc Natl Acad Sci U S A 2009; 106: 17729-34.
195. Ma YQ, Qin J, Wu C, Plow EF. Kindlin-2 (Mig-2): a co-activator of beta3 integrins. J Cell Biol 2008; 181: 439-46.
196. Goult BT, Bouaouina M, Harburger DS, Bate N, Patel B, Anthis NJ, Campbell ID, Calderwood DA, Barsukov IL, Roberts GC, Critchley DR. The structure of the N-terminus of kindlin-1: a domain important for alphaiibbeta3 integrin activation. J Mol Biol 2009; 394: 944-56.
197. Svensson L, Howarth K, McDowall A, Patzak I, Evans R, Ussar S, Moser M, Metin A, Fried M, Tomlinson I, Hogg N. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med 2009; 15: 306-12.
198. Plow EF, Qin J, Byzova T. Kindling the flame of integrin activation and function with kindlins. Curr Opin Hematol 2009; 16: 323-8.
199. Bledzka K, Bialkowska K, Nie H, Qin J, Byzova T, Wu C, Plow EF, Ma YQ. Tyrosine phosphorylation of integrin beta3 regulates kindlin-2 binding and integrin activation. J Biol Chem 2010; 285: 30370-4.
200. Mory A, Feigelson SW, Yarali N, Kilic SS, Bayhan GI, Gershoni-Baruch R, Etzioni A, Alon R. Kindlin-3: a new gene involved in the pathogenesis of LAD-III. Blood 2008; 112: 2591.
201. Kuijpers TW, van de Vijver E, Weterman MA, de BM, Tool AT, van den Berg TK, Moser M, Jakobs ME, Seeger K, Sanal O, Unal S, Cetin M, Roos D, Verhoeven AJ, Baas F. LAD-1/variant syndrome is caused by mutations in FERMT3. Blood 2008; 113: 4740-6.
202. Malinin NL, Zhang L, Choi J, Ciocea A, Razorenova O, Ma YQ, Podrez EA, Tosi M, Lennon DP, Caplan AI, Shurin SB, Plow EF, Byzova TV. A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans. Nat Med 2009; 15: 313-8.
203. Suzuki-Inoue K, Fuller GL, Garcia A, Eble JA, Pohlmann S, Inoue O, Gartner TK, Hughan SC, Pearce AC, Laing GD, Theakston RD, Schweighoffer E, Zitzmann N, Morita T, Tybulewicz VL, Ozaki Y, Watson SP. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 2006; 107: 542-9.
204. Chaipan C, Soilleux EJ, Simpson P, Hofmann H, Gramberg T, Marzi A, Geier M, Stewart EA, Eisemann J, Steinkasserer A, Suzuki-Inoue K, Fuller GL, Pearce AC, Watson SP, Hoxie JA, Baribaud F, Pohlmann S. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol 2006; 80: 8951-60.
205. Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y, Narimatsu H. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 2008; 99: 54-61.
206. Suzuki-Inoue K, Inoue O, Ding G, Nishimura S, Hokamura K, Eto K, Kashiwagi H, Tomiyama Y, Yatomi Y, Umemura K, Shin Y, Hirashima M, Ozaki Y. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem 2010; 285: 24494-507.
207. Bertozzi CC, Schmaier AA, Mericko P, Hess PR, Zou Z, Chen M, Chen CY, Xu B, Lu MM, Zhou D, Sebzda E, Santore MT, Merianos DJ, Stadtfeld M, Flake AW, Graf T, Skoda R, Maltzman JS, Koretzky GA, Kahn ML. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood 2010; 116: 661-70.
208. Suzuki-Inoue K, Inoue O, Ozaki Y. The novel platelet activation receptor CLEC-2. Platelets 2011. In Press.
209. Jones KL, Hughan SC, Dopheide SM, Farndale RW, Jackson SP, Jackson DE. Platelet endothelial cell adhesion molecule-1 is a negative regulator of platelet-collagen interactions. Blood 2001; 98: 1456-63.
210. Cicmil M, Thomas JM, Leduc M, Bon C, Gibbins JM. Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets. Blood 2002; 99: 137-44.
211. Crockett J, Newman DK, Newman PJ. PECAM-1 functions as a negative regulator of laminin-induced platelet activation. J Thromb Haemost 2010; 8: 1584-93.
212. Patil S, Newman DK, Newman PJ. Platelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagen. Blood 2001; 97: 1727-32.
213. Newman PJ. Switched at birth: a new family for PECAM-1. J Clin Invest 1999; 103: 5-9.
214. Mori J, Pearce AC, Spalton JC, Grygielska B, Eble JA, Tomlinson MG, Senis YA, Watson SP. G6b-B inhibits constitutive and agonist-induced signaling by glycoprotein VI and CLEC-2. J Biol Chem 2008; 283: 35419-27.
215. Washington AV, Gibot S, Acevedo I, Gattis J, Quigley L, Feltz R, De La Mota A, Schubert RL, Gomez-Rodriguez J, Cheng J, Dutra A, Pak E, Chertov O, Rivera L, Morales J, Lubkowski J, Hunter R, Schwartzberg PL, McVicar DW. TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans. J Clin Invest 2009; 119: 1489-501.
216. Newman PJ, Gorski J, White GC 2nd, Gidwitz S, Cretney CJ, Aster RH. Enzymatic amplification of platelet-specific messenger RNA using the polymerase chain reaction. J Clin Invest 1988; 82: 739-43.
217. French DL, Seligsohn U. Platelet glycoprotein IIb/IIIa receptors and Glanzmann's thrombasthenia. Arterioscler Thromb Vasc Biol 2000; 20: 607-10.
218. French D, Nurden A, Wilcox DA. Glanzmann thrombasthenia database. Accessed 2 June 2011.
219. Kunishima S, Kamiya T, Saito H. Genetic abnormalities of Bernard-Soulier syndrome. Int J Hematol 2002; 76: 319-27.
220. Miller JL. Platelet-type von Willebrand disease. Thromb Haemost 1996; 75: 865-9.
221. Nurden P, Nurden AT. Congenital disorders associated with platelet dysfunctions. Thromb Haemost 2008; 99: 253-63.
222. Wautier JL, Gruel Y. Prenatal diagnosis of platelet disorders. Baillieres Clin Haematol 1989; 2: 569-83.
223. Seligsohn U, Mibashan RS, Rodeck CH, Nicolaides KH, Millar DS, Coller BS. Prenatal diagnosis of Glanzmann's thrombasthenia. Lancet 1985; 2: 1419.
224. Nichols WL, Rick ME, Ortel TL, Montgomery RR, Sadler JE, Yawn BP, James AH, Hultin MB, Manco-Johnson MJ, Weinstein M. Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol 2009; 84: 366-70.
225. Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24: 123-34.
226. French DL, Coller BS, Usher S, Berkowitz R, Eng C, Seligsohn U, Peretz H. Prenatal diagnosis of Glanzmann thrombasthenia using the polymorphic markers BRCA1 and THRA1 on chromosome 17. Br J Haematol 1998; 102: 582-7.
227. Shulman NR, Aster RH, Leitner A. Immunoreactions involving platelets. V. Post-transfusion purpura due to a complement-fixing antibody against a genetically-controlled platelet antigen: a proposed mechanism for thrombocytopenia and its relevance in "autoimmunity". J Clin Invest 1961; 40: 1597.
228. Morrison FS, Mollison PL. Post-transfusion purpura. N Engl J Med 1966; 275: 243-8.
229. Valentin N, Newman PJ. Human platelet alloantigens. Curr Opin Hematol 1994; 1: 381-7.
230. Newman PJ. Platelet GPIIb-IIIa: molecular variations and alloantigens. Thromb Haemost 1991; 66: 111-8.
231. Gerstner JB, Smith MJ, Davis KD, Cimo PL, Aster RH. Posttransfusion purpura: therapeutic failure of PlAl-negative platelet transfusion. Am J Hematol 1979; 6: 71-5.
232. Skogen B, Husebekk A, Killie MK, Kjeldsen-Kragh J. Neonatal alloimmune thrombocytopenia is not what it was: a lesson learned from a large prospective screening and intervention program. Scand J Immunol 2009; 70: 531-4.
233. Bussel J. Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia. J Thromb Haemost 2009; 7 (Suppl. 1): 253-7.
234. Arnold DM, Smith JW, Kelton JG. Diagnosis and management of neonatal alloimmune thrombocytopenia. Transfus Med Rev 2008; 22: 255-67.
235. Kaplan C. Neonatal alloimmune thrombocytopenia: a 50-year story. Immunohematology 2007; 23: 9-13.
236. Borchgrevink CF, Egeberg O, Godal HC, Hjort PF. The effect of plasma and Cohn's fraction I on the Duke and Ivy bleeding times in von Willebrand's disease. Acta Med Scand 1963; 173: 235-42.
237. Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest 1971; 50: 244-54.
238. Owen WG. Big piece, little piece or: yes, factor VIII is a protein. J Thromb Haemost 2005; 3: 1905-9.
239. Sadler JE. von Willebrand factor assembly and secretion. J Thromb Haemost 2009; 7 (Suppl. 1): 24-7.
240. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
241. Handin RI, Wagner DD. Molecular and cellular biology of von Willebrand factor. Prog Hemost Thromb 1989; 9: 233-59.
242. Ginsburg D. Molecular genetics of von Willebrand disease. Thromb Haemost 1999; 82: 585-91.
243. Gralnick HR, Coller BS, Sultan Y. Carbohydrate deficiency of the factor VIII/von Willebrand factor Protein in von Willebrand's disease variants. Science 1976; 192: 56-9.
244. Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program 2009; 106-12.
245. Franchini M, Mannucci PM. von Willebrand factor: another janus-faced hemostasis protein. Semin Thromb Hemost 2008; 34: 663-9.
246. Lenting PJ, van Schooten CJM, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5: 1353-60.
247. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR, Horne BD, Stewart AF, Assimes TL, Wild PS, Allayee H, Nitschke PL, Patel RS, Martinelli N, Girelli D, Quyyumi AA, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011; 377: 383-92.
248. McGrath RT, McRae E, Smith OP, O'Donnell JS. Platelet von Willebrand factor - structure, function and biological importance. Br J Haematol 2010; 148: 834-43.
249. Wagner DD. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. Thromb Haemost 1993; 70: 105-10.
250. Weiss HJ. von Willebrand factor and platelet function. Ann N Y Acad Sci 1991; 614: 125-37.
251. Howard MA, Firkin BG. Ristocetin - a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh. 1971; 26: 362-9.
252. Howard MA, Sawers RJ, Firkin BG. Ristocetin: a means of differentiating von Willebrand's disease into two groups. Blood 1973; 41: 687-90.
253. Brinkhous KM, Read MS, Reddick RL, Griggs TR. Pathophysiology of platelet-aggregating von Willebrand factor: applications of the venom coagglutinin vWF assay. Ann N Y Acad Sci 1981; 370: 191-204.
254. Hawiger J. Adhesive interactions of platelets and their blockade. Ann N Y Acad Sci 1991; 614: 270-8.
255. Farrell DH. Pathophysiologic roles of the fibrinogen gamma chain. Curr Opin Hematol 2004; 11: 151-5.
256. Smith JW, Ruggeri ZM, Kunicki TJ, Cheresh DA. Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. J Biol Chem 1990; 265: 12267-71.
257. Ugarova TP, Budzynski AZ, Shattil SJ, Ruggeri ZM, Ginsberg MH, Plow EF. Conformational changes in fibrinogen elicited by its interaction with platelet membrane glycoprotein GPIIb-IIIa. J Biol Chem 1993; 268: 21080-7.
258. Vorup-Jensen T, Carman CV, Shimaoka M, Schuck P, Svitel J, Springer TA. Exposure of acidic residues as a danger signal for recognition of fibrinogen and other macromolecules by integrin alphaXbeta2. Proc Natl Acad Sci U S A 2005; 102: 1614-9.
259. Podolnikova NP, Gorkun OV, Loreth RM, Yee VC, Lord ST, Ugarova TP. A cluster of basic amino acid residues in the gamma370-381 sequence of fibrinogen comprises a binding site for platelet integrin alpha(IIb)beta3 (glycoprotein IIb/IIIa). Biochemistry 2005; 44: 16920-30.
260. Hamaguchi M, Bunce LA, Sporn LA, Francis CW. Spreading of platelets on fibrin is mediated by the amino terminus of the beta chain including peptide beta 15-42. Blood 1993; 81: 2348-56.
261. Endenburg SC, Hantgan RR, Sixma JJ, de Groot PG, Zwaginga JJ. Platelet adhesion to fibrin(ogen). Blood Coagul Fibrinolysis 1993; 4: 139-42.
262. Jirouskova M, Dyr JE, Suttnar J, Holada K, Trnkova B. Platelet adhesion to fibrinogen, fibrin monomer, and fibrin protofibrils in flowing blood - the effect of fibrinogen immobilization and fibrin formation. Thromb Haemost 1997; 78: 1125-31.
263. Hainaud P, Brouland JP, Andre P, Simoneau G, Bal Dit Sollier C, Drouet L, Caen J, Bellucci S. Dissociation between fibrinogen and fibrin interaction with platelets in patients with different subtypes of Glanzmann's thrombasthenia: studies in an ex vivo perfusion chamber model. Br J Haematol 2002; 119: 998-1004.
264. Cho J, Degen JL, Coller BS, Mosher DF. Fibrin but not adsorbed fibrinogen supports fibronectin assembly by spread platelets. Effects of the interaction of alphaIIb beta3 with the C terminus of the fibrinogen gamma-chain. J Biol Chem 2005; 280: 35490-8.
265. Niewiarowski S, Levy-Toledano S, Caen JP. Platelet interaction with polymerizing fibrin in Glanzmann's thrombasthenia. Thromb Res 1981; 23: 457-63.
266. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-5.
267. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-103.
268. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
269. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-6.
270. Caramazza D, Quintini G, Abbene I, Malato A, Saccullo G, Lo Coco L, Di Trapani R, Palazzolo R, Barone R, Mazzola G, Rizzo S, Ragonese P, Aridon P, Abbadessa V, Siragusa S. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Transfusion 2010; 50: 2753-60.
271. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
272. Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 1960; 16: 943-57.
273. Upshaw JD Jr. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978; 298: 1350-2.
274. Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 2004; 41: 68-74.
275. Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010; 31: 11-9.
276. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC, Knobl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 105: 545-52.
277. Galbusera M, Noris M, Remuzzi G. Thrombotic thrombocytopenic purpura - then and now. Semin Thromb Hemost 2006; 32: 81-9.
278. Brand A, Novotny V, Tomson B. Platelet transfusion therapy: from 1973 to 2005. Hum Immunol 2006; 67: 413-8.
279. National Institutes of Health Consensus Conference. Platelet transfusion therapy. Transfus Med Rev 1987; 1: 195-200.
280. Schiffer CA. Management of patients refractory to platelet transfusion - an evaluation of methods of donor selection. Prog Hematol 1987; 15: 91-113.
281. Heyman MR, Schiffer CA. Platelet transfusion therapy for the cancer patient. Semin Oncol 1990; 17: 198-209.
282. Slichter SJ. Platelet transfusion therapy. Hematol Oncol Clin North Am 1990; 4: 291-311.
283. Carmen R. The selection of plastic materials for blood bags. Transfus Med Rev 1993; 7: 1-10.
284. Murphy S. Metabolic patterns of platelets - impact on storage for transfusion. Vox Sang 1994; 67 (Suppl. 3): 271-3.
285. Rinder HM, Arbini AA, Snyder EL. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol 1999; 6: 437-41.
286. Pamphilon DH. The rationale and use of platelet concentrates irradiated with ultraviolet-B light. Transfus Med Rev 1999; 13: 323-33.
287. Murphy S. The efficacy of synthetic media in the storage of human platelets for transfusion. Transfus Med Rev 1999; 13: 153-63.
288. Roddie PH, Turner ML, Williamson LM. Leucocyte depletion of blood components. Blood Rev 2000; 14: 145-56.
289. Corash L. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes. Baillieres Best Pract Res Clin Haematol 2000; 13: 549-63.
290. Beutler E. Platelet transfusions: the 20, 000/μssL trigger. Blood 1993; 81: 1411-3.
291. Sorensen DK, Cronkite EP, Bond VP. Effectiveness of transfusions of fresh and lyophilized platelets in controlling bleeding due to thrombocytopenia. J Clin Invest 1959; 38: 1689.
292. Alving BM. Platelet substitutes: the reality and the potential. Vox Sang 2002; 83 (Suppl. 1): 287-8.
293. George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program 2009; 153-8.
294. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008; 112: 2607-16.
295. Cines DB, Rauova L, Arepally G, Reilly MP, McKenzie SE, Sachais BS, Poncz M. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher 2007; 22: 31-6.
296. Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Hussein S, Alt C, Menchaca D, Tomita D, Marty J, Fox RM, Begley CG. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348: 1279-81.
297. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelka AP, Freedman RS, Edwards CL, Gershenson D, Jones D, Ashby M, Kavanagh JJ. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000; 132: 364-8.
298. Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA, Heil G, Fenaux P, Brugger W, Barge A, O'Brien-Ewen C, Matcham J, Hoelzer D. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999; 94: 3694-701.
299. Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 2000; 26: 141-5.
300. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-8.
301. Kuter DJ. Romiplostim. Cancer Treat Res 2011; 157: 267-88.
302. Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109: 4607-16.
303. Molineux G. The development of romiplostim for patients with immune thrombocytopenia. Ann N Y Acad Sci 2011; 1222: 55-63.
304. Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol 2010; 47: 243-8.
305. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377: 393-402.
306. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227-36.
307. Cuker A. Toxicities of the thrombopoietic growth factors. Semin Hematol 2010; 47: 289-98.
308. Dultz G, Kronenberger B, Azizi A, Mihm U, Vogl TJ, Sarrazin U, Sarrazin C, Zeuzem S, Hofmann WP. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. J Hepatol 2011. [Epub ahead of print].
309. Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009; 35: 189-203.
310. Kunishima S, Saito H. Advances in the understanding of MYH9 disorders. Curr Opin Hematol 2010; 17: 405-10.
311. Jorgensen L, Rowsell HC, Hovig T, Glynn MF, Mustard JF. Adenosine diphosphate-induced platelet aggregation and myocardial infarction in swine. Lab Invest 1967; 17: 616-44.
312. Jorgensen L. ADP-induced platelet aggregation in the microcirculation of pig myocardium and rabbit kidneys. J Thromb Haemost 2005; 3: 1119-24.
313. Weiss HJ. The discovery of the antiplatelet effect of aspirin: a personal reminiscence. J Thromb Haemost 2003; 1: 1869-75.
314. Folts JD, Crowell EB Jr, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-70.
315. Jack DB. One hundred years of aspirin. Lancet 1997; 350: 437-9.
316. Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation 2011; 123: 768-78.
317. Douthwaite AH, Lintott GAM. Gastroscopic observation of the effect of aspirin and certain other substances on the stomach. Lancet 1938; 2: 1222.
318. Craven LL. Prevention of coronary and cerebral thrombosis. Miss Valley Med J 1956; 78: 213-5.
319. Quick AJ. Bleeding Problems in Clinical Medicine. Philadelphia, PA: WB Saunders, 1970.
320. Rapoport S, Wing M, Guest GM. Hypoprothrombinemia after salicy-late administration in man and rabbits. Proc Soc Exp Biol Med 1943; 53: 40.
321. Weiss HJ, Aledort LM. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 1967; 2: 495-7.
322. Zucker MB, Peterson J. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proc Soc Exp Biol Med 1968; 127: 547-51.
323. Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968; 47: 2169-80.
324. O'Brien JR. Effect of salicylates on human platelets. Lancet 1968; 1: 1431.
325. Evans G, Packham MA, Nishizawa EE, Mustard JF, Murphy EA. The effect of acetylsalicyclic acid on platelet function. J Exp Med 1968; 128: 877-94.
326. Zucker MB. Platelet physiology: a personal perspective. Platelets 1990; 1: 3-9.
327. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971; 231: 235-7.
328. Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol 1971; 231: 237-9.
329. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5.
330. Marcus AJ. The role of prostaglandins in platelet function. Prog Hematol 1979; 11: 147-71.
331. Samuelsson B. From studies of biochemical mechanism to novel biological mediators: prostaglandin endoperoxides, thromboxanes, and leukotrienes. Nobel Lecture, 8 December 1982. BiosciRep 1983; 3: 791-813.
332. Hamberg M, Svensson J, Wakabayashi T, Samuelsson B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci U S A 1974; 71: 345-9.
333. Ricciotti E, Fitzgerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31: 986-1000.
334. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2: 637-43.
335. Mann CC, Plummer ML. The aspirin wars: money, medicine, and 100years of rampant competition. New York, NY: Harvard Business School Press, 1991.
336. Antiplatelet Trialists C. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res) 1988; 396: 320-31.
337. US Food and Drug Administration. Tentative final monograph. Notice of proposed rule-making for internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Fed Reg 1988; 53: 46204-58.
338. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
339. Barnathan ES, Schwartz JS, Taylor L, Laskey WK, Kleaveland JP, Kussmaul WG, Hirshfeld JW Jr. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987; 76: 125-34.
340. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
341. Aspirin for the prevention of cardiovascular disease: US. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 396-404.
342. Tran HA, Anand SS, Hankey GJ, Eikelboom JW. Aspirin resistance. Thromb Res 2007; 120: 337-46.
343. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, Michelson AD. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008; 6: 2035-44.
344. Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009; 120: 2586-96.
345. Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol 2008; 28: s25-32.
346. Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events - a meta-analysis. Int J Cardiol 2008; 128: 166-71.
347. Podesta M, Aubert D, Ferrand JC. Contribution a l'etude pharmacologique de thienopyridines et d'analogues furanniques. Eur J Med Chem 1974; 9: 487-90.
348. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
349. Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Saf 1998; 19: 89-98.
350. CAPRIE steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
351. Raju NC, Eikelboom JW, Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med 2008; 5: 766-80.
352. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 2281-5.
353. Kunapuli SP, Daniel JL. P2 receptor subtypes in the cardiovascular system. Biochem J 1998; 336 (Pt 3): 513-23.
354. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
355. Balamuthusamy S, Arora R. Hematologic adverse effects of clopidogrel. Am J Ther 2007; 14: 106-12.
356. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
357. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
358. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-57.
359. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
360. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304: 1821-30.
361. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-11.
362. Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, Giacomoni MP, Bonello R, Collet F, Rossi P, Barragan P, Dignat-George F, Paganelli F. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103: 5-10.
363. Cuisset T, Frere C, Quilici J, Morange PE, Mouret JP, Bali L, Moro PJ, Lambert M, Alessi MC, Bonnet JL. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 2008; 1: 649-53.
364. Cattaneo M. Resistance to anti-platelet agents. Thromb Res 2011; 127 (Suppl. 3): S61-3.
365. Bouman HJ, Schomig E, van Werkum JW, Velder J, Hackeng CM, Hirschhauser C, Waldmann C, Schmalz HG, ten Berg JM, Taubert D. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-6.
366. Tomasello SD, Tello-Montoliu A, Angiolillo DJ. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. Expert Opin Investig Drugs 2011; 20: 119-33.
367. Paikin JS, Eikelboom JW, Cairns JA, Hirsh J. New antithrombotic agents - insights from clinical trials. Nat Rev Cardiol 2010; 7: 498-509.
368. Abergel E, Nikolsky E. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Vasc Health Risk Manag 2010; 6: 963-77.
369. Gurbel PA, Kereiakes DJ, Tantry US. Ticagrelor for the treatment of arterial thrombosis. Expert Opin Pharmacother 2010; 11: 2251-9.
370. Gaglia MA Jr, Waksman R. Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor. Circulation 2011; 123: 451-6.
371. Serebruany VL. Paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 10-2.
372. Ueno M, Ferreiro JL, Angiolillo DJ. Update on the clinical development of cangrelor. Expert Rev Cardiovasc Ther 2010; 8: 1069-77.
373. Oestreich JH. Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs 2010; 11: 340-8.
374. Ueno M, Rao SV, Angiolillo DJ. Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Fut Card 2010; 6: 445-53.
375. Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997; 99: 1467-71.
376. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995; 92: 2373-80.
377. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci 1991; 614: 193-213.
378. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997; 80: 11B-20B.
379. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993; 268: 1066-73.
380. Barrett JS, Murphy G, Peerlinck K, De Lepeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, Arnout J. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994; 56: 377-88.
381. Hartman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, Naylor AM, Manno PD, Lynch RJ, Zhang G, Chang C, Gould RP. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J Med Chem 1992; 35: 4640-2.
382. Bosch X, Marrugat J, Sanchis J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane Database Syst Rev 2010; doi: .
383. Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Circ Cardiovasc Interv 2009; 2: 230-6.
384. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J 2009; 30: 2705-13.
385. Hanna EB, Rao SV, Manoukian SV, Saucedo JF. The evolving role of glycoprotein IIb/IIIa inhibitors in the setting of percutaneous coronary intervention strategies to minimize bleeding risk and optimize outcomes. JACC Cardiovasc Interv 2010; 3: 1209-19.
386. Aster RH, Curtis BR, Bougie DW, Dunkley S, Greinacher A, Warkentin TE, Chong BH. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost 2006; 4: 678-9.
387. Hansen PR, Iversen A, Abdulla J. Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Invasive Cardiol 2010; 22: 278-82.
388. Gibson CM, Maehara A, Lansky AJ, Wohrle J, Stuckey T, Dave R, Cox D, Grines C, Dudek D, Steg G, Parise H, Wolff SD, Cristea E, Stone GW. Rationale and design of the INFUSE-AMI study: a 2×2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. Am Heart J 2011; 161: 478-86.
389. Hassan AK, Jukema JW, van der Laarse A, Hasan-Ali H, Wolterbeek R, van der Kley F, Spano F, Atsma DE, Schalij MJ. Incidence, patient characteristics and predictors of aborted myocardial infarction in patients undergoing primary PCI: prospective study comparing pre- and in-hospital abciximab pretreatment. EuroIntervention 2009; 4: 662-8.
390. Godicke J, Flather M, Noc M, Gyongyosi M, Arntz HR, Grip L, Gabriel HM, Huber K, Nugara F, Schroder J, Svensson L, Wang D, Zorman S, Montalescot G. Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. Am Heart J 2005; 150: 1015.
391. Smit JJ, van Werkum JW, ten Berg J, Slingerland R, Ottervanger JP, Heestermans T, Dill T, Hamm C, van 't Hof AW. Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. Heart 2010; 96: 1815-20.
392. Cox D. Oral GPIIb/IIIa antagonists: what went wrong? Curr Pharm Des 2004; 10: 1587-96.
393. Chew DP, Bhatt DL, Topol EJ. Oral glycoprotein IIb/IIIa inhibitors: why don't they work? Am J Cardiovasc Drugs 2001; 1: 421-8.
394. Zhu J, Negri A, Provasi D, Filizola M, Coller BS, Springer TA. The closed headpiece of integrin {alpha}IIb{beta}3 and its complex with an {alpha}IIb{beta}3-specific antagonist that does not induce opening. Blood 2010; 116: 5050-9.
395. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
396. Oestreich J. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. Curr Opin Investig Drugs 2009; 10: 988-96.
397. Wolters Kluwer's Adis. Vorapaxar. Am J Cardiovasc Drugs 2010; 10: 413-8.
398. Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 2010; 31: 2601-13.
399. Qu Z, Chaikof EL. Interface between hemostasis and adaptive immunity. Curr Opin Immunol 2010; 22: 634-42.
400. Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A 2006; 103: 855-60.
401. Italiano JE Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227-33.
402. Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. J Thromb Haemost 2011. [Epub before print].
403. Ma AC, Kubes P. Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis. J Thromb Haemost 2008; 6: 415-20.
404. Echtler K, Stark K, Lorenz M, Kerstan S, Walch A, Jennen L, Rudelius M, Seidl S, Kremmer E, Emambokus NR, von Bruehl ML, Frampton J, Isermann B, Genzel-Boroviczeny O, Schreiber C, Mehilli J, Kastrati A, Schwaiger M, Shivdasani RA, Massberg S. Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med 2010; 16: 75-82.
405. Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet C, Bader M, Clavien PA. Platelet-derived serotonin mediates liver regeneration. Science 2006; 312: 104-7.
406. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968; 61: 46-52.
407. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11: 123-34.
408. Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 2010; 30: 2362-7.
409. Feng W, Madajka M, Kerr BA, Mahabeleshwar GH, Whiteheart SW, Byzova TV. A novel role for platelet secretion in angiogenesis: mediating bone marrow-derived cell mobilization and homing. Blood 2011; 117: 3893-3902.
410. Tung SS, Parmar S, Robinson SN, De Lima M, Shpall EJ. Ex vivo expansion of umbilical cord blood for transplantation. Best Pract Res Clin Haematol 2010; 23: 245-57.
411. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16: 232-6.
412. Fujimoto TT, Kohata S, Suzuki H, Miyazaki H, Fujimura K. Production of functional platelets by differentiated embryonic stem (ES) cells in vitro. Blood 2003; 102: 4044-51.
413. Kennedy M, Keller GM. Hematopoietic commitment of ES cells in culture. Methods Enzymol 2003; 365: 39-59.
414. Gaur M, Kamata T, Wang S, Moran B, Shattil SJ, Leavitt AD. Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function. J Thromb Haemost 2006; 4: 436-42.
415. Takayama N, Nishikii H, Usui J, Tsukui H, Sawaguchi A, Hiroyama T, Eto K, Nakauchi H. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 2008; 111: 5298-306.
416. Gekas C, Graf T. Induced pluripotent stem cell-derived human platelets: one step closer to the clinic. J Exp Med 2010; 207: 2781-4.
417. Lu SJ, Li F, Yin H, Feng Q, Kimbrel EA, Hahm E, Thon JN, Wang W, Italiano JE, Cho J, Lanza R. Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice. Cell Res 2011; 21: 530-45.
418. Takayama N, Nishimura S, Nakamura S, Shimizu T, Ohnishi R, Endo H, Yamaguchi T, Otsu M, Nishimura K, Nakanishi M, Sawaguchi A, Nagai R, Takahashi K, Yamanaka S, Nakauchi H, Eto K. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med 2010; 207: 2817-30.